Purinergic Regulation of Vascular Endothelial Growth Factor Signaling in Angiogenesis

Overview

Journal Br J Cancer

Specialty Oncology

Date 2009 Apr 16

PMID 19367276

Citations 32

Authors

S M Rumjahn

N Yokdang

K A Baldwin

J Thai

I L O Buxton

Affiliations

Soon will be listed here.

Abstract

P2Y purine nucleotide receptors (P2YRs) promote endothelial cell tubulogenesis through breast cancer cell-secreted nucleoside diphosphate kinase (NDPK). We tested the hypothesis that activated P2Y(1) receptors transactivate vascular endothelial growth factor receptor (VEGFR-2) in angiogenic signaling. P2Y(1)R stimulation (10 microM 2-methyl-thio-ATP (2MS-ATP)) of angiogenesis is suppressed by the VEGFR-2 tyrosine kinase inhibitor, SU1498 (1 microM). Phosphorylation of VEGFR-2 by 0.0262 or 2.62 nM VEGF was comparable with 0.01 or 10 microM 2MS-ATP stimulation of the P2Y(1)R. 2MS-ATP, and VEGF stimulation increased tyrosine phosphorylation at tyr1175. 2MS-ATP (0.1-10 microM) also stimulated EC tubulogenesis in a dose-dependent manner. The addition of sub-maximal VEGF (70 pM) in the presence of increasing concentrations of 2MS-ATP yielded additive effects at 2MS-ATP concentrations <3 microM, whereas producing saturated and less than additive effects at > or =3 microM. We propose that the VEGF receptor can be activated in the absence of VEGF, and that the P2YR-VEGFR2 interaction and resulting signal transduction is a critical determinant of vascular homoeostasis and tumour-mediated angiogenesis.

Citing Articles

Acute vascular and cardiac effects of lenvatinib in mice.

Kruger D, Pannucci P, Wesley C, Neutel C, Martinet W, De Meyer G Cardiooncology. 2025; 11(1):14.

PMID: 39934897 PMC: 11816767. DOI: 10.1186/s40959-025-00307-8.

Metastasis and angiogenesis in cervical cancer: key aspects of purinergic signaling in platelets and possible therapeutic targets.

Faria P, Resende R, Cardoso A Purinergic Signal. 2024; 20(6):607-616.

PMID: 38753131 PMC: 11554953. DOI: 10.1007/s11302-024-10020-3.

The Pleiotropic Role of Extracellular ATP in Myocardial Remodelling.

Sudi S, Thomas F, Daud S, Daud D, Sunggip C Molecules. 2023; 28(5).

PMID: 36903347 PMC: 10004151. DOI: 10.3390/molecules28052102.

Purinergic receptors are a key bottleneck in tumor metabolic reprogramming: The prime suspect in cancer therapeutic resistance.

Aria H, Rezaei M, Nazem S, Daraei A, Nikfar G, Mansoori B Front Immunol. 2022; 13:947885.

PMID: 36072596 PMC: 9444135. DOI: 10.3389/fimmu.2022.947885.

Extracellular Vesicle-Mediated Metastasis Suppressors NME1 and NME2 Modify Lipid Metabolism in Fibroblasts.

Matyasi B, Petovari G, Danko T, Butz H, Liko I, Low P Cancers (Basel). 2022; 14(16).

PMID: 36010906 PMC: 9406105. DOI: 10.3390/cancers14163913.

References

Sakurai Y, Ohgimoto K, Kataoka Y, Yoshida N, Shibuya M . Essential role of Flk-1 (VEGF receptor 2) tyrosine residue 1173 in vasculogenesis in mice. Proc Natl Acad Sci U S A. 2005; 102(4):1076-81. PMC: 545830. DOI: 10.1073/pnas.0404984102. View

Jackson S, Hoshi T, Wu Y, Sun X, Enjyoji K, Cszimadia E . Disordered purinergic signaling inhibits pathological angiogenesis in cd39/Entpd1-null mice. Am J Pathol. 2007; 171(4):1395-404. PMC: 1988887. DOI: 10.2353/ajpath.2007.070190. View

Seye C, Yu N, Gonzalez F, Erb L, Weisman G . The P2Y2 nucleotide receptor mediates vascular cell adhesion molecule-1 expression through interaction with VEGF receptor-2 (KDR/Flk-1). J Biol Chem. 2004; 279(34):35679-86. DOI: 10.1074/jbc.M401799200. View

Rumjahn S, Javed M, Wong N, Law W, Buxton I . Purinergic regulation of angiogenesis by human breast carcinoma-secreted nucleoside diphosphate kinase. Br J Cancer. 2007; 97(10):1372-80. PMC: 2360243. DOI: 10.1038/sj.bjc.6604019. View

Kaczmarek E, Erb L, Koziak K, Jarzyna R, Wink M, Guckelberger O . Modulation of endothelial cell migration by extracellular nucleotides: involvement of focal adhesion kinase and phosphatidylinositol 3-kinase-mediated pathways. Thromb Haemost. 2005; 93(4):735-42. PMC: 2830093. DOI: 10.1160/TH04-09-0576. View

Tanaka N, Nejime N, Kagota S, Kubota Y, Yudo K, Nakamura K . ATP participates in the regulation of microvessel permeability. J Pharm Pharmacol. 2006; 58(4):481-7. DOI: 10.1211/jpp.58.4.0007. View

Holmqvist K, Cross M, Rolny C, Hagerkvist R, Rahimi N, Matsumoto T . The adaptor protein shb binds to tyrosine 1175 in vascular endothelial growth factor (VEGF) receptor-2 and regulates VEGF-dependent cellular migration. J Biol Chem. 2004; 279(21):22267-75. DOI: 10.1074/jbc.M312729200. View

Goepfert C, Sundberg C, Sevigny J, Enjyoji K, Hoshi T, Csizmadia E . Disordered cellular migration and angiogenesis in cd39-null mice. Circulation. 2001; 104(25):3109-15. DOI: 10.1161/hc5001.100663. View

Satterwhite C, Farrelly A, Bradley M . Chemotactic, mitogenic, and angiogenic actions of UTP on vascular endothelial cells. Am J Physiol. 1999; 276(3):H1091-7. DOI: 10.1152/ajpheart.1999.276.3.H1091. View

10.

Pollard J . Tumour-educated macrophages promote tumour progression and metastasis. Nat Rev Cancer. 2004; 4(1):71-8. DOI: 10.1038/nrc1256. View

11.

Benjamin L, Golijanin D, Itin A, Pode D, Keshet E . Selective ablation of immature blood vessels in established human tumors follows vascular endothelial growth factor withdrawal. J Clin Invest. 1999; 103(2):159-65. PMC: 407882. DOI: 10.1172/JCI5028. View

12.

Erlinge D, Burnstock G . P2 receptors in cardiovascular regulation and disease. Purinergic Signal. 2008; 4(1):1-20. PMC: 2245998. DOI: 10.1007/s11302-007-9078-7. View

13.

Buxton I, KAISER R, Oxhorn B, Cheek D . Evidence supporting the Nucleotide Axis Hypothesis: ATP release and metabolism by coronary endothelium. Am J Physiol Heart Circ Physiol. 2001; 281(4):H1657-66. DOI: 10.1152/ajpheart.2001.281.4.H1657. View

14.

Okabe-Kado J, Kasukabe T . Physiological and pathological relevance of extracellular NM23/NDP kinases. J Bioenerg Biomembr. 2003; 35(1):89-93. DOI: 10.1023/a:1023402125186. View

15.

Arora A, Scholar E . Role of tyrosine kinase inhibitors in cancer therapy. J Pharmacol Exp Ther. 2005; 315(3):971-9. DOI: 10.1124/jpet.105.084145. View

16.

Strawn L, McMahon G, App H, Schreck R, Kuchler W, Longhi M . Flk-1 as a target for tumor growth inhibition. Cancer Res. 1996; 56(15):3540-5. View

17.

Ewan L, Jopling H, Jia H, Mittar S, Bagherzadeh A, Howell G . Intrinsic tyrosine kinase activity is required for vascular endothelial growth factor receptor 2 ubiquitination, sorting and degradation in endothelial cells. Traffic. 2006; 7(9):1270-82. DOI: 10.1111/j.1600-0854.2006.00462.x. View

18.

White N, Burnstock G . P2 receptors and cancer. Trends Pharmacol Sci. 2006; 27(4):211-7. DOI: 10.1016/j.tips.2006.02.004. View

19.

Tanaka N, Kawasaki K, Nejime N, Kubota Y, Nakamura K, Kunitomo M . P2Y receptor-mediated Ca(2+) signaling increases human vascular endothelial cell permeability. J Pharmacol Sci. 2004; 95(2):174-80. DOI: 10.1254/jphs.fpj03036x. View

20.

Gounaris K, Thomas S, Najarro P, Selkirk M . Secreted variant of nucleoside diphosphate kinase from the intracellular parasitic nematode Trichinella spiralis. Infect Immun. 2001; 69(6):3658-62. PMC: 98361. DOI: 10.1128/IAI.69.6.3658-3662.2001. View